Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research ...
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY ...
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...
FiercePharma7h
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...
Le Lézard8h
Top Companies, Marketers, CEOs, Products, and Initiatives Were Celebrated During Trailblazer Gala on October 1st
On Tuesday night, October 1st, at a gala event held at Gotham Hall in New York City, PM360 announced the winners of its 16th annual Trailblazer Awards. In total, PM360, a leading life sciences ...
Sanofi inks $1B deal to sell autoimmune disorder therapy
Sanofi (SNY) sells global rights to Enjaymo treatment for cold agglutinin disease to Recordati (RCDTF) in a deal worth up to ...
Taiwan News22h
Japan Pruritus Therapeutics Market to Reach $1.01B by 2032 | 6.33% CAGR
Japan Pruritus Therapeutics Market was valued at US$ 582.2 million in 2023 and is estimated to surpass the market size of US$ 1,011.5 million by 2032 at a CAGR of 6.33% during the forecast period 2024 ...